Katarzyna Jerzak

Dr. Katarzyna Jerzak


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2020 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
MKMarkus Kuksis
Markus Kuksis
YGYizhuo Gao
Yizhuo Gao
WTWilliam Tran
William Tran
CHChristianne Hoey
Christianne Hoey
AKAlex Kiss
Alex Kiss
KJKatarzyna Jerzak
Katarzyna Jerzak
Background: Patients with metastatic breast cancer (MBC) are living longer, but the development of brain metastases often limits their survival. We conducted a systematic review and meta-analysis to determine the incidence of brain metastases in this patient population.Methods: Articles published from January 2000 to January 2020 were compiled from four databases using search terms related to breast cancer, brain metastasis, and incidence. The overall and per patient-year incidence of brain metastases were extracted from studies including patients with human epidermal growth factor receptor-2 positive (HER2+), triple negative, and hormone receptor (HR)+/hormone receptor negative (HER2−) MBC; pooled overall estimates for incidence were calculated using random effects models.Results: 937 articles were compiled, and 25 were included in the meta-analysis. Incidence of brain metastases in patients with HER2+ MBC, triple negative MBC, and HR+/HER2− MBC was reported in 17, 6, and 4 studies, respectively. The pooled cumulative incidence of brain metastases was 31% for the HER2+ subgroup (median follow-up: 30.7 months, IQR: 24.0–34.0), 32% for the triple negative subgroup (median follow-up: 32.8 months, IQR: 18.5–40.6), and 15% among patients with HR+/HER2− MBC (median follow-up: 33.0 months, IQR: 31.9–36.2). The corresponding incidences per patient-year were 0.13 (95% CI: 0.10–0.16) for the HER2+ subgroup, 0.13 (95%CI: 0.09–0.20) for the triple negative subgroup, and only 0.05 (95%CI: 0.03–0.08) for patients with HR+/HER2− MBC.Conclusion: There is a high incidence of brain metastases among patients with HER2+ and triple negative MBC. The utility of a brain metastases screening program warrants investigation in these populations.

3 October 2018 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
YRYasmeen Razvi
Yasmeen Razvi
SCStephanie Chan
Stephanie Chan
TMThomas McFarlane
Thomas McFarlane
EMErin McKenzie
Erin McKenzie
PZPearl Zaki
Pearl Zaki
KJKatarzyna Jerzak
Katarzyna Jerzak

1 April 2018 in Current Oncology
Verified
Journal Article
Open access
KJKatarzyna Jerzak
Katarzyna Jerzak
TMT. Mancuso
T. Mancuso
AEA. Eisen
A. Eisen
Background: Despite the fact that heterozygosity for a pathogenic ATM variant is present in 1%–2% of the adult population, clinical guidelines to inform physicians and genetic counsellors about optimal management in that population are lacking. Methods: In this narrative review, we describe the challenges and controversies in the management of women who are heterozygous for a pathogenic ATM variant with respect to screening for breast and other malignancies, to choices for systemic therapy, and to decisions about radiation therapy. Results: Given that the lifetime risk for breast cancer in women who are heterozygous for a pathogenic ATM variant is likely greater than 25%, those women should undergo annual mammographic screening starting at least by 40 years of age. For women in this group who have a strong family history of breast cancer, earlier screening with both magnetic resonance imaging and mammography should be considered. High-quality data to inform the management of established breast cancer in carriers of pathogenic ATM variants are lacking. Although deficiency in the ATM gene product might confer sensitivity to DNA-damaging pharmaceuticals such as inhibitors of poly (ADP–ribose) polymerase or platinum agents, prospective clinical trials have not been conducted in the relevant patient population. Furthermore, the evidence with respect to radiation therapy is mixed; some data suggest increased toxicity, and other data suggest improved clinical benefit from radiation in women who are carriers of a pathogenic ATM variant. Conclusions: As in the 2017 U.S. National Comprehensive Cancer Network guidelines, we recommend high-risk imaging for women in Ontario who are heterozygous for a pathogenic ATM variant. Currently, ATM carrier status should not influence decisions about systemic or radiation therapy in the setting of an established breast cancer diagnosis.

22 December 2020 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
SHSteven Habbous
Steven Habbous
KFKatharina Forster
Katharina Forster
GDGail E Darling
Gail E Darling
KJKatarzyna Jerzak
Katarzyna Jerzak
CHClaire M B Holloway
Claire M B Holloway
SDSunit Das
Sunit Das
Although intracranial metastatic disease (IMD) is a frequent complication of cancer, most cancer registries do not capture these cases. Consequently, a data-gap exists, which thwarts system-level quality improvement efforts. The purpose of this investigation was to determine the real-world burden of IMD. Patients diagnosed with a non-CNS cancer between 2010 and 2018 were identified from the Ontario Cancer Registry. IMD was identified by scanning hospital administrative databases for cranial irradiation or coding for a secondary brain malignancy (ICD-10 code C793). 25,478 of 601,678 (4.2%) patients with a diagnosis of primary cancer were found to have IMD. The median time from primary cancer diagnosis to IMD was 5.2 (0.7, 15.4) months and varied across disease sites, for example, 2.1 months for lung, 7.3 months for kidney, and 22.8 months for breast. Median survival following diagnosis with IMD was 3.7 months. Lung cancer accounted for 60% of all brain metastases, followed by breast cancer (11%) and melanoma (6%). More advanced stage at diagnosis and younger age were associated with a higher likelihood of developing IMD (P < .0001). IMD was also associated with triple-negative breast cancers and ductal histology (P < .001), and with small-cell histology in patients with lung cancer (P < .0001). The annual incidence of IMD was 3,520, translating to 24.2 per 100,000 persons. IMD represents a significant burden in patients with systemic cancers and is a significant cause of cancer mortality. Our findings support measures to actively capture incidents of brain metastasis in cancer registries.

1 February 2020 in Clinical Breast Cancer
Verified
Journal Article
Closed access
AKAdam S. Komorowski
Adam S. Komorowski
EWEllen Warner
Ellen Warner
HMHelen J. MacKay
Helen J. MacKay
ASArjun Sahgal
Arjun Sahgal
KPKathleen I. Pritchard
Kathleen I. Pritchard
KJKatarzyna Jerzak
Katarzyna Jerzak

29 October 2019 in Oncotarget
Verified
Journal Article
Open access
PDF file
Long NguyenLong Nguyen
Long Nguyen
KSKarlee Searle
Karlee Searle
KJKatarzyna Jerzak
Katarzyna Jerzak
Oncotarget | https://doi.org/10.18632/oncotarget.27238 Long V. Nguyen, Karlee Searle, Katarzyna J. Jerzak